Provention bio announces closing of second tranche with hercules capital to support u.s. commercial launch of tzield®

Red bank, n.j. , feb. 2, 2023 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with hercules capital, inc. (nyse: htgc), a leader in customized financing for companies in life sciences.
PRVB Ratings Summary
PRVB Quant Ranking